Neoleish, developed by the Petia subsidiary together with the Higher Council for Scientific Research, is the first for animal mammals and the second in the world with this technology.
Petia Vet Health, a subsidiary of the Zendal group, launches the first vaccine for animal mammals based on Recombinant DNA to face the leishmaniasis caninaa parasite that causes everything from skin ulcers to severe inflammation of the liver and spleen.
The vaccine Neoleishdeveloped by the group Zendal with a team from the Higher Council for Scientific Research (CSIC) is the first in animal mammals and the second in the world with this technology, based on fragments of genetic information that encode immunogens.
The European Medicines Agency At the end of 2022, it issued a favorable opinion on this vaccine, which reduces the presence of the parasite in dogs by 90%, the main carriers of the parasite and the main reservoir of visceral leishmaniasis.
Now the final step of putting it on the market is taken, a launch that takes place within the framework of IBERZOO+Proppet International Fair for pet professionals held at Ifema, in Madrid.
Effectiveness
He CSIC researcher Vicente Larragafrom the Molecular Parasitology group of the Margarita Salas Biological Research Center (CIB-CSIC), and director of development, emphasizes that this vaccine stands out for being “very effective”, since it reduces the number of parasites in vaccinated dogs by 92% in a parallel experiment carried out in the laboratory.
He parasitic protozoan enters the cells of the animal’s immune system, which it infects and thus protects itself from the antibodies it generates to eliminate it. Therefore, for its protection, “it requires the activation of the so-called cellular pathway (the well-known killer cells and T lymphocytes), to be eliminated,” says Vicente Larraga.
The vaccine specifically activates the cellular defense pathway in infected animals and reduces the presence of the parasite within the cells of vaccinated dogs. In addition, it allows the active immunization of Leishmania negative dogs from 6 months of age, to reduce the risk of developing an active infection and/or clinical disease after exposure to Leishmania infantum.
For his part, the general director of Petia, Ricardo Troncoso, He assured that “this is an important milestone for the company, given the importance of this vaccine in the pet health environment, to which it will provide greater health and safety.”
“Once again, the union of public-private synergies gives a good result in the biopharmaceutical field. The Zendal-CSIC alliance has achieved a milestone in animal vaccinology,” highlighted the Zendal CEO, Andrés Fernándezwho has also stressed that there is “a safe vaccine, belonging to the most innovative group, the so-called third generation vaccine.”
La Leishmaniasis
Leishmaniasis is a disease caused by the Leishmania parasite, of the trypanosomatid family, which is carried by the sand fly. It is a zoonosis grave (which means it is transmitted from animals to humans), present in the Mediterranean basin, Asia and America which can cause death without treatment and whose main reservoir is the dog.
Las clinical manifestations of the disease range from skin ulcers that heal spontaneously to fatal forms in which it occurs severe inflammation of the liver and spleen. Every year there are between 500,000 and one million new cases and, in Spain, it is estimated that almost 30% of dogs have had contact with the parasite.
2024-03-13 18:04:47
#Zendal #launches #DNA #technology #vaccine #canine #leishmaniasis
